Literatur
-
1 Bericht der Arbeitsgruppe „Gesamtstrategie Blutversorgung angesichts vCJK” August 2001; . http://www.pei.de/pm/2001/gesamtstrategie_bericht.pdf
-
2
Prusiner S B.
Shattuck lecture: Neurodegenerative disorders and prions.
N Engl J Med.
2001;
344
1516
-
3
Aguzzi A, Montrasio F, Kaeser P S.
Prions: Health care and biological challenge.
Nature Reviews Molecular Cell Biology.
2001;
2
218
-
4
Johnson R T, Gibbs C J.
Creutzfeldt-Jacob disease and related transmissible spongiform encephalopathies.
N Engl J Med.
1998;
339
1994
-
5
Robert-Koch-Institut .
Creutzfeldt-Jakob-Erkrankung (CJK) bzw. humane übertragbare (transmissible) spongiforme Enzephalopathien (TSE).
Bundesgesundheitsblatt.
1998;
41
78
-
6
Simon D, Pauli G.
Krankenversorgung und Instrumentensterilisation bei CJK-Patienten und CJK-Verdachtsfällen.
Bundesgesundheitsblatt.
1998;
41
279
-
7
van Duijn C M, Delsnerie-Laupetre N, Masullo C. et al .
Case control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-1995.
Lancet.
1998;
351
1081
-
8
Collins S, Law M G, Fletcher A. et al .
Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study.
Lancet.
1999 ;
353
693
-
9
Will R G, Ironside J W, Zeidler M. et al .
A new variant of Creutzfeldt-Jakob disease in the UK.
Lancet.
1996 ;
347
921
-
10
Collinge J.
Variant Creutzfeldt-Jakob disease.
Lancet.
1999 ;
354
317
-
11 Department of Health .Monthly Creutzfeldt-Jakob disease statistics. http://www.doh.gov.uk/cjd/stats Januar/2002
-
12
Ghani A C, Ferguson N M, Donelly C A. et al .
Predicted vCJD mortality in Great Britain.
Nature.
2000 ;
406
583
-
13
Valleron A J, Boelle P Y, Will R. et al .
Estimating of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom.
Science.
2001;
294
1726
-
14
Jackson G S, Beck J A, Navarette C, Brown J, Sutton P M, Contreras M, Collinge J.
HLA-DQ7 antigen and resistance to variant CJD.
Nature.
2001;
414
269
-
15
Klein M A, Frigg R, Flechsig E. et al .
A crucial role for B cells in neuroinvasive scrapie.
Nature.
1997;
390
687
-
16
Brown P, Cernevakova L, Diringer H.
Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jacob disease.
J Lab Clin Med.
2001;
137
5
-
17
Houston F, Foster J D, Chong A. et al .
Transmission of BSE by blood transfusion in sheep.
Lancet.
2000;
356
99
-
18
Butler D.
Brain mix-up leaves BSE research in turmoil.
Nature.
2001 a;
413
760
-
19
Butler D.
Poor practices led to BSE brains mix-up, says auditors.
Nature.
2001 b;
414
569
-
20
Lasmezas C I, Fournier J G, Nouvel V. et al .
Adaption of the bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-Jacob disease: Implications for human health.
Proc Natl Acad Sci.
2001;
98
4142
-
21 Contreras B. Persönliche Mitteilung. Dezember/2001
-
22
Saborio G P, Permanne B, Soto C.
Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding.
Nature.
2001;
411
810
-
23 Heiden M. Persönliche Mitteilung. Januar/2002
-
24 Agence francaise de securite sanitaire des produits de sante (AFSSPS) .Analyse du risque de transmission de la nouvelle variante de la maladie de Creutzfeldt-Jakob par le sang et ses derives. 11 .decembre.2000
-
25
Bender A W.
Creutzfeldt-Jacob-Erkrankung und ärztliche Aufklärungspflicht vor der Anwendung von Blutprodukten.
Medizinrecht.
2001;
19
221
Korrespondenzadresse:
Prof. Dr. med. Michael Köhler
Abteilung Transfusionsmedizin Universitätsklinik Göttingen
Robert-Koch-Straße 40
37075 Göttingen